Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who ...

Mauricio Umansky has been open about the rare blood disease he suffered from as a child. Read on to learn more about it.

Tivic Health (TIVC) announced that it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod for a second ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

In 2006, Casarett published a case report in the AMA Journal of Ethics describing a patient with lung cancer who experienced a series of hospitalizations, including for febrile neutropenia, a common ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.